Viera Martha H, Amini Sadegh, Valins Whitney, Berman Brian
University of Miami, Miller School of Medicine, Department of Dermatology and Cutaneous Surgery, Miami, Florida.
J Clin Aesthet Dermatol. 2010 May;3(5):20-6.
Keloids and hypertrophic scars are benign fibrous overgrowths of scar tissue, which results from an abnormal response to trauma. Several therapeutic modalities have been described for the treatment and prevention of these conditions, but the optimal management approach has not yet been defined. This article reviews the most recent, innovative, therapeutic strategies for the management of hypertrophic scars and keloids, including mitomycin-C, tamoxifen citrate, methotrexate, imidazolaquinolines, retinoids, calcineurin inhibitors, phenylakylamine calcium channel blockers, botulinum toxin, vascular endothelial growth factor inhibitors, hepatocyte growth factor, basic fibroblast growth factor, interleukin-10, manosa-6-phosphate, transforming growth factor beta, antihistamines, and prostaglandin E2. No consensus in treatment regimens has been reached due to the limited evidence-based information found in the literature. Most therapeutic options have potential effectiveness as both monotherapy and as combination therapy. However, recent reports offer novel modalities that may approach scarring from different angles.
瘢痕疙瘩和增生性瘢痕是瘢痕组织的良性纤维过度生长，由对创伤的异常反应引起。已经描述了几种用于治疗和预防这些病症的治疗方法，但尚未确定最佳的管理方法。本文综述了治疗增生性瘢痕和瘢痕疙瘩的最新、创新治疗策略，包括丝裂霉素-C、枸橼酸他莫昔芬、甲氨蝶呤、咪唑喹啉类、维甲酸、钙调神经磷酸酶抑制剂、苯烷基胺钙通道阻滞剂、肉毒杆菌毒素、血管内皮生长因子抑制剂、肝细胞生长因子、碱性成纤维细胞生长因子、白细胞介素-10、甘露糖-6-磷酸、转化生长因子β、抗组胺药和前列腺素E2。由于文献中基于证据的信息有限，尚未就治疗方案达成共识。大多数治疗选择作为单一疗法和联合疗法都有潜在疗效。然而，最近的报告提供了可能从不同角度解决瘢痕形成问题的新方法。
